Home Companies Catalysts Deep Dives
Kineret anakinra APPROVED
Drug Profile
ModalityRecombinant protein
RouteSC
Therapy AreaImmunology
Launch2001-11-14
Peak Sales Est$350M
Formulations[{"id":"kineret-sc","doses":"100 mg SC daily (RA); weight-based for CAPS/Still/FMF","route":"SC","de
Companies
SOBI (ORIGINATOR)100%
Mechanism: IL-1β inhibitor
Expert: Monoclonal antibody targeting interleukin-1 beta
Everyday: Blocks an inflammatory protein that causes fever and inflammation
Targets: ["IL-1B"]
Revenue History
PeriodRevenue ($M)
2024$300M
Q4 2025$71M
Programs (2)
IndicationStageKey StudyRegional Status
CAPS (FCAS/MWS/NOMID)APPROVEDPivotal CAPS studies[{"notes":"FDA approved for NOMID (2013). Broad CAPS use.","stage":"APPROVED","r
Still's Disease (sJIA / AOSD)APPROVEDPhase 3 Still studies[{"notes":"Approved for Still's disease","stage":"APPROVED","region":"US"},{"not
Notes
IL-1 receptor antagonist. One of the oldest biologics (approved 2001). Multiple rare disease indications: CAPS (cryopyrin-associated periodic syndromes), Still's disease, FMF (familial Mediterranean fever), DIRA. Also approved for RA but rarely used there (superseded by anti-TNF). Stable legacy revenue. Japan registration for Still's disease ongoing.
Data from Supabase · Updated 2026-03-24